Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis

BMC Res Notes. 2022 Dec 12;15(1):368. doi: 10.1186/s13104-022-06263-1.

Abstract

Objective: Competition among trials for patient enrollment can impede recruitment. We hypothesized that this occurred early in the COVID-19 pandemic, when an unprecedented number of clinical trials were launched. We performed a simple and multivariable regression analysis evaluating the relationship between the proportion of SARS-CoV-2 investigational trial sites within each USA state with unsuccessful patient-participant recruitment and: (i) the proportion of cases required to reach state recruitment goals; (ii) state population based on data from the US Census; and, (iii) number of trial sites per state.

Results: Our study included 151 clinical trials. The proportion of trials with successful recruitment was 72.19% (109 of 151 trials). We did not find a significant relationship between unsuccessful patient-participant recruitment, state recruitment goals, state population or the number of trial sites per state in both our simple and multivariable regression analyses. Our results do not suggest that early in the COVID-19 pandemic, competition for patient-participants impeded successful recruitment in SARS-CoV-2 trials. This may reflect the unique circumstances of the first few months of the pandemic in the United States, in which the number and location of SARS-CoV-2 cases was sufficient to meet trial recruitment requirements, despite the large number of trials launched.

Keywords: COVID-19; Clinical trials; Competition; Patient-participant recruitment; SARS-CoV-2; United States.

MeSH terms

  • COVID-19* / epidemiology
  • Cohort Studies
  • Humans
  • Pandemics
  • Patient Selection
  • SARS-CoV-2*
  • United States / epidemiology